Targeted therapy in melanoma

References

• HoodJDBednarskiMFraustoRTumor regression by targeted gene delivery to the neovasculatureScience20022962404240712089446
   PubMed Web of Science ®Google Scholar
• Gray-SchopferVWellbrockCMaraisRMelanoma biology and new targeted therapyNature200744585185717314971
   PubMed Web of Science ®Google Scholar
• SatyamoorthyKLiGGerreroMRConstitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulationCancer Res20036375675912591721
   PubMed Web of Science ®Google Scholar
• LyonsJFWilhelmSHibnerBBollagGDiscovery of a novel Raf kinase inhibitorEndocr Relat Cancer2001821922511566613
   PubMed Web of Science ®Google Scholar
• WilhelmSChienDSBAY 43-9006: Preclinical dataCurr Pharm Des200282255225712369853
   PubMed Web of Science ®Google Scholar
• WilhelmSMCarterCTangLBAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the raf/mek/erk pathway and receptor tyrosine kinases involved in tumor progression and angiogenesisCancer Res2004647099710915466206
   PubMed Web of Science ®Google Scholar
• PankaDJWangWAtkinsMBMierJWThe Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cellsCancer Res2006661611161916452220
   PubMed Web of Science ®Google Scholar
• RahmaniMDavisEMBauerCDentPGrantSApoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translationJ Biol Chem2005280352173522716109713
   PubMed Web of Science ®Google Scholar
• YuCBruzekLMMengXWThe role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006Oncogene2005246861686916007148
   PubMed Web of Science ®Google Scholar
• GraellsJVinyalsAFiguerasAOverproduction of vegf concomitantly expressed with its receptors promotes growth and survival of melanoma cells through mapk and pi3k signalingJ Invest Dermatol20041231151116115610528
   PubMed Web of Science ®Google Scholar
• EscudierBEisenTStadlerWMSorafenib in advanced clear-cell renal-cell carcinomaN Engl J Med200735612513417215530
   PubMed Web of Science ®Google Scholar
• StrumbergDClarkJWAwadaASafety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumorsOncologist20071242643717470685
   PubMed Web of Science ®Google Scholar
• RatainMJEisenTStadlerWMPhase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinomaJ Clin Oncol2006242505251216636341
   PubMed Web of Science ®Google Scholar
• ChatelutEDelordJPCanalPToxicity patterns of cytotoxic drugsInvest New Drugs20032114114812889735
   PubMed Web of Science ®Google Scholar
• HauschildAAgarwalaSSTrefzerUResults of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanomaJ Clin Oncol200927172823283019349552
   PubMed Web of Science ®Google Scholar
• EisenTAhmadTMaraisRPhase I trial of sorafenib (BAY 43-9006) combined with dacarbazine (DTIC) in patients with metastatic melanoma [abstract]Eur J Cancer Suppl20053349
   Google Scholar
• EisenTMaraisRAffolterAAn open-label phase ii study of sorafenib and dacarbazine as first line therapy in patients with advanced melanoma [abstract]J Clin Oncol2007258529
   Google Scholar
• McDermottDFSosmanJAGonzalezRDouble-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: A report from the 11715 study groupJ Clin Oncol2008262178218518445842
   PubMed Web of Science ®Google Scholar
• AmaravadiRSchuchterLMMcDermottDFUpdated results of a randomized phase ii study comparing two schedules of temozolomide in combination with sorafenib in patiets with advanced melanoma [abstract]J Clin Oncol2007258527
   Google Scholar
• SoriaJLazarVLassauNSorafenib (S) and dacarbazine (D) combination in patients (pts) with advanced malignant solid tumors: Phase I study with tumor biopsy genomic analysis and dynamic contrast enhanced ultrasonography (DCE-US) [abstract]J Clin Oncol2007253556
   Web of Science ®Google Scholar
• FlahertyKPuzanovISosmanJPhase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer [abstract]J Clin Oncol200927Suppl 159000
   Web of Science ®Google Scholar
• TarhiniAAKirkwoodJMOblimersen in the treatment of metastatic melanomaFuture Oncol2007326327117547520
   PubMedGoogle Scholar
• GentaIGenta’s lead antisense drug reported active in malignant melanoma new data on antisense mechanism and clinical response reported in leading journalMedia Release2000
   Google Scholar
• JansenBWacheckVHeere-RessEChemosensitisation of malignant melanoma by BCL2 antisense therapyLancet20003561728173311095261
   PubMed Web of Science ®Google Scholar
• PavlickACEscalonJMaddenKA phase I/II study to determine the feasibility and efficacy of the triple combination of oblimersen (OBL), abraxane (ABX), and temozolomide (TMZ) in metastatic melanoma and normal LDHJ Clin Oncol200826Suppl9027
   Web of Science ®Google Scholar
• BedikianAYMillwardMPehambergerHBcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study GroupJ Clin Oncol2006244738474516966688
   PubMed Web of Science ®Google Scholar
• LevDCOnnAMelinkovaVOExposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivoJ Clin Oncol2004222092210015123733
   PubMed Web of Science ®Google Scholar
• JainRKNormalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapyNature Med2001798798911533692
   PubMed Web of Science ®Google Scholar
• NörJEChristensenJMooneyDJPolveriniPJVascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expressionAm J Pathol199915437538410027396
   PubMed Web of Science ®Google Scholar
• MasoodRCaiJZhengTSmithDLHintonDRGillPSVascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumorsBlood2001981904191311535528
   PubMed Web of Science ®Google Scholar
• LacalPMFaillaCMPaganiEHuman melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factorJ Invest Dermatol20001151000100711121133
   PubMed Web of Science ®Google Scholar
• VarkerKABiberJEKefauverCA randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanomaAnn Surg Oncol2007142367237617534686
   PubMed Web of Science ®Google Scholar
• SandlerAGrayRPerryMCPaclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerN Engl J Med20063552542255017167137
   PubMed Web of Science ®Google Scholar
• KabbinavarFFHambletonJMassRDHurwitzHIBergslandESarkarSCombined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancerJ Clin Oncol2005233706371215867200
   PubMed Web of Science ®Google Scholar
• PerezDGSumanVJFitchTRPhase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047 ACancer200911511912719090009
   PubMed Web of Science ®Google Scholar
• GeraJFMellinghoffIKShiYAKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expressionJ Biol Chem20042792737274614576155
   PubMed Web of Science ®Google Scholar
• NeshatMSMellinghoffIKTranCEnhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTORProc Natl Acad Sci U S A200198103141031911504908
   PubMed Web of Science ®Google Scholar
• SchmelzleTHallMNTOR, a central controller of cell growthCell200010325326211057898
   PubMed Web of Science ®Google Scholar
• HuangSHoughtonPJMechanisms of resistance to rapamycinsDrug Resist Updat2001437839112030785
   PubMed Web of Science ®Google Scholar
• RaymondEAlexandreJDepenbrockHCCI-779, a rapamycin analog with antitumor activity: A phase I study utilizing a weekly schedule [abstract]Proc Am Soc Clin Oncol200019187
   Google Scholar
• PeralbaJMDeGraffenriedLFriedrichsWPharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patientsClin Cancer Res200392887289212912932
   PubMed Web of Science ®Google Scholar
• DutcherJPHudesGMotzerRPreliminary report of a phase 1 study of intravenous (IV) CCI-779 given in combination with interferon- (IFN) to patients with advanced renal cell carcinoma (RCC) [abstract]Proc Am Soc Clin Oncol200322213
   Web of Science ®Google Scholar
• AdamsJPalombellaVJSausvilleEAProteasome inhibitors: A novel class of potent and effective antitumor agentsCancer Res1999592615262210363983
   PubMed Web of Science ®Google Scholar
• LingYHLiebesLJiangJDMechanisms of proteasome inhibitor PS-341-induced G2-M-Phase arrest and apoptosis in human non-small cell lung cancer cell linesClin Cancer Res200391145115412631620
   PubMed Web of Science ®Google Scholar
• NagataYAnanTYoshidaTThe stabilization mechanism of mutant-type p53 by impaired ubiquitination: The loss of wild-type p53 function and the hsp90 associationOncogene1999186037604910557093
   PubMed Web of Science ®Google Scholar
• AnWGHwangSGTrepelJBBlagosklonnyMVProtease inhibitorinduced apoptosis: Accumulation of wt p53, p21waf1/cip1, and induction of apoptosis are independent markers of proteasome inhibitionLeukemia2000141276128310914553
   PubMed Web of Science ®Google Scholar
• AlessandriniAChiaurDSPaganoMRegulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylationLeukemia1997113423459067571
   PubMed Web of Science ®Google Scholar
• PalombellaVJConnerEMFuselerJWRole of the proteasome and nf-kappab in streptococcal cell wall-induced polyarthritisProc Natl Acad Sci U S A19989515671156769861028
   PubMed Web of Science ®Google Scholar
• ReadMANeishASLuscinskasFWPalombellaVJManiatisTCollinsTThe proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expressionImmunity199524935067538441
   PubMed Web of Science ®Google Scholar
• NixDPienCNewmanRClinical development of a proteasome inhibitor, PS-341, for the treatment of cancerProc Am Soc Clin Oncol20012086a
   Google Scholar
• MarkovicSNGeyerSMDawkinsFA phase II study of bortezomib in the treatment of metastatic malignant melanomaCancer20051032584258915887220
   PubMed Web of Science ®Google Scholar
• KendraKLLesinskiGBOlenckiTECarsonWA phase I study of bortezomib and interferon-alpha-2b in patients with metastatic melanoma [abstract]J Clin Oncol2008
   Web of Science ®Google Scholar
• RobertsJDErnstoffMSBirdsellCPhase I trial of dacarbazine and bortezomib in melanoma and soft tissue sarcoma [abstract]J Clin Oncol2006
   Google Scholar
• Dal LagoLD’HondtVAwadaASelected combination therapy with sorafenib: A review of clinical data and perspectives in advanced solid tumorsOncologist20081384585818695262
   PubMed Web of Science ®Google Scholar
• HaassNKSproesserKNguyenTKThe mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxelClin Cancer Res20081423023918172275
   PubMed Web of Science ®Google Scholar
• SmalleyKSHaassNKBraffordPALioniMFlahertyKTHerlynMMultiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastasesMol Cancer Ther200651136114416731745
   PubMed Web of Science ®Google Scholar
• AdjeiAACohenRBFranklinWPhase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancersJ Clin Oncol2008262139214618390968
   PubMed Web of Science ®Google Scholar
• DummerRRobertCChapmanPBAZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study [abstract ]J Clin Oncol200826Suppl9033
   Web of Science ®Google Scholar
• RajkumarSVThalidomide in the treatment of multiple myelomaExpert Rev Anticancer Ther20011202812113124
   PubMedGoogle Scholar
• QuilitzRThalidomide in oncology: The peril and the promiseCancer Control1999648349510758580
   PubMedGoogle Scholar
• MoreiraALSampaioEPZmuidzinasAFrindtPSmithKAKaplanGThalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradationJ Exper Med1993177167516808496685
   PubMed Web of Science ®Google Scholar
• GeitzHHandtSZwingenbergerKThalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascadeImmunopharmacology1996312132218861747
   PubMed Web of Science ®Google Scholar
• GuptaDTreonSPShimaYAdherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applicationsLeukemia2001151950196111753617
   PubMed Web of Science ®Google Scholar
• DaviesFERajeNHideshimaTThalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myelomaBlood20019821021611418482
   PubMed Web of Science ®Google Scholar
• MeierhoferCWiedermannCJNew insights into the pharmacological and toxicological effects of thalidomideCurr Opin Drug Discov Devel200369299
   PubMed Web of Science ®Google Scholar
• FranksMEMacphersonGRFiggWDThalidomideLancet20043631802181115172781
   PubMed Web of Science ®Google Scholar
• MeierhoferCDunzendorferSWiedermannCJTheoretical basis for the activity of thalidomideBioDrugs20011568170311604049
   PubMed Web of Science ®Google Scholar
• MitsiadesNMitsiadesCSPoulakiVApoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implicationsBlood2002994525453012036884
   PubMed Web of Science ®Google Scholar
• AtkinsMBSosmanJAAgarwalaSTemozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: A phase II cytokine working group studyCancer20081132139214518792064
   PubMed Web of Science ®Google Scholar
• OttPAChangJLOratzRPhase II trial of dacarbazine and thalidomide for the treatment of metastatic melanomaChemotherapy20095522122719451711
   PubMed Web of Science ®Google Scholar
• VestermarkLWLarsenSLindelovBBastholtLA phase II study of thalidomide in patients with brain metastases from malignant melanomaActa Oncol2008471526153018607876
   PubMed Web of Science ®Google Scholar
• VaishampayanUNHeilbrunLKMarsackCSmithDWFlahertyLEPhase II trial of pegylated interferon and thalidomide in malignant metastatic melanomaAnticancer Drugs2007181221122617893524
   PubMed Web of Science ®Google Scholar